Related Experiment Video
Updated: May 2, 2026

04:41
Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
18.9K
Construction of a Dataset for All Expressed Transcripts for Alzheimer's Disease Research
Zhenyu Huang1,2, Bocheng Shi2,3, Xuechen Mu2,3
1College of Computer Science and Technology, Jilin University, Changchun 130012, China.
Brain Sciences
|January 8, 2025
Summary
This study created an improved transcriptome resource for Alzheimer's disease (AD) research, enhancing the identification of gene transcripts and long non-coding RNAs (lncRNAs) to better understand disease mechanisms.
Area of Science:
- Transcriptomics
- Bioinformatics
- Neuroscience
Background:
- Gene misregulation and metabolic reprogramming are key in Alzheimer's disease (AD).
- Existing AD transcript databases lack comprehensive identification of splicing isoforms and long non-coding RNAs (lncRNAs).
Purpose of the Study:
- To generate a comprehensive and accurate transcriptome resource for AD.
- To improve existing AD transcript databases by refining annotation of splicing isoforms and lncRNAs.
Main Methods:
- Utilized publicly available RNA-sequencing data from pre-AD and AD tissues.
- Applied advanced bioinformatics tools for transcript assembly and annotation.
- Focused on correcting errors and enhancing annotation accuracy for full-length transcripts, splicing isoforms, and lncRNAs.
Main Results:
- Generated a significantly improved transcriptome dataset for AD.
- Included detailed annotations of splicing isoforms and lncRNAs, expanding existing AD transcript databases.
- The refined dataset captures more relevant details of AD progression compared to publicly available data.
Conclusions:
- The developed transcriptome resource offers valuable insights into AD molecular mechanisms.
- Supports future research on gene regulation and metabolic reprogramming in AD.
- Provides a foundation for identifying novel therapeutic targets for Alzheimer's disease.
Related Concept Videos
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35

